Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in ACLF disease models Safety data from Phase 1 ...
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results for the first nine months of 2025. Almirall continues to deliver its sustained growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback